-

Affiliates of Blackstone Real Estate Complete $3.6 Billion Acquisition of Bluerock Residential Growth REIT

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced that affiliates of Blackstone Real Estate (“Blackstone”) have completed the previously announced acquisition of Bluerock Residential Growth REIT, Inc. (“Bluerock”) for $24.25 per share in an all-cash transaction valued at $3.6 billion.

Bluerock has also completed the previously announced spin-off of its single-family rental business into an externally managed, real estate investment trust, Bluerock Homes Trust, Inc. (NYSE American: BHM) (“BHM”). BHM began trading on the New York Stock Exchange American this morning.

Barclays and Wells Fargo Securities LLC served as Blackstone’s financial advisors, and Simpson Thacher & Bartlett LLP as Blackstone’s legal advisor. Morgan Stanley & Co. LLC and Eastdil Secured LLC served as Bluerock’s lead financial advisors with BofA Securities also serving as an advisor. Wachtell, Lipton, Rosen & Katz, KVCF, PLC, and Vinson & Elkins, LLP served as Bluerock’s legal counsel.

The transaction was announced on December 20, 2021.

About Blackstone Real Estate

Blackstone is a global leader in real estate investing. Blackstone’s real estate business was founded in 1991 and has US $320 billion of investor capital under management. Blackstone is the largest owner of commercial real estate globally, owning and operating assets across every major geography and sector, including logistics, residential, office, hospitality and retail. Our opportunistic funds seek to acquire undermanaged, well-located assets across the world. Blackstone’s Core+ business invests in substantially stabilized real estate assets globally, through both institutional strategies and strategies tailored for income-focused individual investors including Blackstone Real Estate Income Trust, Inc. (BREIT), a U.S. non-listed REIT, and Blackstone’s European yield-oriented strategy. Blackstone Real Estate also operates one of the leading global real estate debt businesses, providing comprehensive financing solutions across the capital structure and risk spectrum, including management of Blackstone Mortgage Trust (NYSE: BXMT).

Contacts

Jillian Kary
212-583-5379
Jillian.Kary@Blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Jillian Kary
212-583-5379
Jillian.Kary@Blackstone.com

More News From Blackstone

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom